The FDA granted Incyte orphan status for parsaclisib and ruxolitinib, its treatment of myelofibrosis. Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INCY:
- Incyte announces Japanese MHLW approval of Pemazyre
- Incyte upgraded to Market Perform at SVB after ruxolitinib XR CRL, Zynz approval
- Incyte upgraded to Market Perform from Underperform at SVB Securities
- BofA sees minimal near-term impact on Incyte from ruxolitinib ER CRL
- Incyte provides regulatory update on Ruxolitinib extended relief
Questions or Comments about the article? Write to editor@tipranks.com